References

1. Moore KW, de Waal Malefyt R, Coffman RL et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765, (Review).

2. Chernoff AE, Granowitz EV, Shapiro L et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 1995; 15:154(10):5492-9.

3. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy—review of a new approach. Pharmacol Rev 2003; 55(2):241-69, (Review).

4. Tilg H, van Montfrans C, van den Ende A et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 2002;

5. Hutchings A, Wu J, Asiedu C et al. The immune decision toward allograft tolerance in nonhuman primates requires early inhibition of innate immunity and induction of immune regulation. Transpl Immunol 2003; 11(3-4):335-44.

6. Donckier V, Loi P, Closset J et al. Preconditioning of donors with interleukin-10 reduces hepatic ischemia-reperfusion injury after liver transplantation in pigs. Transplantation 2003; 75(6):902-4.

7. Li W, Fu F, Lu L et al. Differential effects of exogenous interleukin-10 on cardiac allograft survival: Inhibition of rejection by recipient pretreatment reflects impaired host accessory cell function. Transplantation 1999; 68(9):1402-9.

8. Zou XM, Yagihashi A, Hirata K et al. Downregulation of cytokine-induced neutrophil chemoattractant and prolongation of rat liver allograft survival by interleukin-10. Surg Today 1998;

28:184-191.

9. Eye Bank Association of America (1998). Eye Bank Association of America Annual Report: 1997-1998.

10. Torres PF, de Vos AF, Martins B et al. Interleukin 10 treatment does not prolong experimental corneal allograft survival. Ophthalmic Res 1999; 31:297-303.

11. Wissing KM, Morelon E, Legendre C et al. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy. Transplantation 1997; 64:999-1006.

12. Bacchetta R, Bigler M, Touraine JL et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 1994; 179(2):493-502.

13. Baker KS, Roncarolo MG, Peters C et al. High spontaneous IL-10 production in unrelated bone marrow transplant recipients is associated with fewer transplant-related complications and early deaths. Bone Marrow Transplant 1999; 23(11):1123-9.

14. Holler E, Roncarolo MG, Hintermeier-Knabe R et al. Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25(3):237-41.

15. Roncarolo MG, Bacchetta R, Bordignon C et al. Type 1 T regulatory cells. Immunol Rev 2001; 182:68-79, (Review).

16. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat Med 2001; 7(1):33-40, (Review).

17. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 28:288(5466):669-72.

18. Nishikawa M, Huang L. Nonviral vectors in the new millennium: Delivery barriers in gene transfer. Hum Gene Ther 2001; 12(8):861-70, (Review).

19. Walther W, Stein U. Viral vectors for gene transfer: A review of their use in the treatment of human diseases. Drugs 2000; 60:249-71, (Review).

20. de Waal Malefyt R, Abrams J, Bennett B et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991a; 174(5):1209-20.

21. de Waal Malefyt R, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991b; 174(4):915-24.

22. DeBruyne LA, Li K, Chan SY et al. Lipid-mediated gene transfer of viral IL-10 prolongs vascular-ized cardiac allograft survival by inhibiting donor-specific cellular and humoral immune responses. Gene Ther 1998; 5(8):1079-87.

23. Hong YS, Laks H, Cui G et al. Localized immunosuppression in the cardiac allograft induced by a new liposome-mediated IL-10 gene therapy. J Heart Lung Transplant 2002; 21(11):1188-200.

24. Itano H, Mora BN, Zhang W et al. Lipid-mediated ex vivo gene transfer of viral interleukin 10 in rat lung allotransplantation. J Thorac Cardiovasc Surg 2001; 122(1):29-38.

25. Konig Merediz SA, Zhang EP, Wittig B et al. Hoffmann F. Ballistic transfer of minimalistic im-munologically defined expression constructs for IL4 and CTLA4 into the corneal epithelium in mice after orthotopic corneal allograft transplantation. Graefes Arch Clin Exp Ophthalmol 2000; 238(8):701-7.

26. Fischbein MP, Yun J, Laks H et al. Regulated interleukin-10 expression prevents chronic rejection of transplanted hearts. J Thorac Cardiovasc Surg 2003; 126(1):216-23.

27. Qin L, Chavin KD, Ding Y et al. Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model. Immunosuppression with TGF-beta 1 or vIL-10. Transplantation 1995; 27:59(6):809-16.

28. Brauner R, Nonoyama M, Laks H et al. Intracoronary adenovirus-mediated transfer of immunosuppressive cytokine genes prolongs allograft survival. J Thorac Cardiovasc Surg 1997; 114(6):923-33.

29. Qin L, Ding Y, Pahud DR et al. Adenovirus-mediated gene transfer of viral interleukin-10 inhibits the immune response to both alloantigen and adenoviral antigen. Hum Gene Ther 1997; 8(11):1365-74.

30. Ding Y, Qin L, Kotenko SV et al. A single amino acid determines the immunostimulatory activity of interleukin 10. J Exp Med 2000; 191(2):213-24.

31. David A, Chetritt J, Guillot C et al. Interleukin-10 produced by recombinant adenovirus prolongs survival of cardiac allografts in rats. Gene Ther 2000; 7(6):505-10.

32. Fischer S, Liu M, MacLean AA et al. In vivo transtracheal adenovirus-mediated transfer of human interleukin-10 gene to donor lungs ameliorates ischemia-reperfusion injury and improves early posttransplant graft function in the rat. Hum Gene Ther 2001; 12:1513-1526.

33. Klebe S, Sykes PJ, Coster DJ et al. Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation 2001; 71:1214-1220.

34. Kato H, Fieblinger C, Ke B et al. Synergistic effects of cytokine gene transfer in high responder rat renal allograft recipients. Transplantation 1999; 67:S570.

35. Goudy K, Song S, Wasserfall C et al. Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice. Proc Natl Acad Sci USA 2001; 98:13913-13918.

36. Yang Z, Chen M, Wu R et al. Suppression of autoimmune diabetes by viral IL-10 gene transfer. J Immunol 2002; 168:6479-6485.

37. Zhang YC, Pileggi A, Agarwal A et al. Adeno-associated virus-mediated IL-10 gene therapy inhibits diabetes recurrence in syngeneic islet cell transplantation of NOD mice. Diabetes 2003; 52:708-716.

38. Takayama T, Nishioka Y, Lu L et al. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation 1998; 66:1567-1574.

39. Coates PT, Krishnan R, Kireta S et al. Human myeloid dendritic cells transduced with an adenoviral interleukin-10 gene construct inhibit human skin graft rejection in humanized NOD-scid chimeric mice. Gene Ther 2001; 8:1224-1233.

40. Lee WC, Qiani S, Wan Y et al. Contrasting effects of myeloid dendritic cells transduced with an adenoviral vector encoding interleukin-10 on organ allograft and tumour rejection. Immunology 2000; 101:233-241.

40a. Van Montfraus C, Rodriguez Pena MS, Prouk I et al. Prevention of colitis by interleukin-10 transduced T lymphocytes in the SCID mice transfer model. Gastroenterology 2002; 123:(6):1865-1876.

41. Murakami Y, Akahoshi T, Kawai S et al. Antiinflammatory effect of retrovirally transfected interleukin-10 on monosodium urate monohydrate crystal-induced acute inflammation in murine air pouches. Arthritis Rheum 2002; 46:2504-2513.

42. Oh JW, Seroogy CM, Meyer EH et al. CD4 T-helper cells engineered to produce IL-10 prevent allergen-induced airway hyperreactivity and inflammation. J Allergy Clin Immunol 2002; 110:460-468.

43 Hall BM, Jelbart ME, Gurley KE et al. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Mediation of specific suppression by T helper/ inducer cells. J Exp Med 1985; 162:1683-1694.

44. Qin S, Cobbold SP, Pope H et al. "Infectious" transplantation tolerance. Science 1993; 259:974-977.

45. Onodera K, Lehmann M, Akalin E et al. Induction of "infectious" tolerance to MHC-incompatible cardiac allografts in CD4 monoclonal antibody-treated sensitized rat recipients. J Immunol 1996; 157:1944-1950.

46. Zhai Y, Kupiec-Weglinski JW. What is the role of regulatory T cells in transplantation tolerance? Curr Opin Immunol 1999; 11:497-503, (Review).

47. Waldmann H, Cobbold S. Regulating the immune response to transplants. A role for CD4+ regulatory cells? Immunity 2001; 14:399-406, (Review).

48. Battaglia M, Blazar BR, Roncarolo MG. The puzzling world of murine T regulatory cells. Microbes Infect 2002; 4:559-66, (Review).

49. Karim M, Bushell AR, Wood KJ. Regulatory T cells in transplantation. Curr Opin Immunol 2002; 14:584-591.

50. Levings MK, Bacchetta R, Schulz U et al. The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 2002; 129:263-276.

51. Shevach EM. CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2002; 2:389-400.

52. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3:199-210.

53. Hara M, Kingsley CI, Niimi M et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001; 166(6):3789-96.

54. Groux H, O'Garra A, Bigler M et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737-742.

55. Chen ZM, O'Shaughnessy MJ, Gramaglia I et al. IL-10 and TGF-beta induce alloreactive CD4+CD25- T cells to acquire regulatory cell function. Blood 2003; 101:5076-5083.

56. Barrat FJ, Cua DJ, Boonstra A et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)-and Th2-inducing cytokines. J Exp Med 2002; 4:195(5):603-16.

57. Nussler NC, Muller AR, Weidenbach H et al. IL-10 increases tissue injury after selective intestinal ischemia/reperfusion. Ann Surg 2003; 238(1):49-58.

Was this article helpful?

0 0
Natural Treatments For Psoriasis

Natural Treatments For Psoriasis

Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.

Get My Free Ebook


Post a comment